Integra LifeSciences (NASDAQ:IART) Price Target Cut to $15.00 by Analysts at BMO Capital Markets

Integra LifeSciences (NASDAQ:IART) had its price objective reduced by BMO Capital Markets from $18.00 to $15.00 in a report issued on Monday morning,Benzinga reports. They currently have a market perform rating on the life sciences company’s stock.

Other research analysts have also issued reports about the company. Weiss Ratings lowered Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Thursday, June 18th. Wall Street Zen lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company set a $15.00 target price on shares of Integra LifeSciences in a report on Saturday. Finally, Truist Financial raised shares of Integra LifeSciences to a “hold” rating in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and an average target price of $17.29.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $13.29 on Monday. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -147.65, a PEG ratio of 0.65 and a beta of 1.21. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. The company’s 50-day moving average is $16.56 and its two-hundred day moving average is $15.22.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. Analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Paradigm Capital Management Inc. NY increased its position in Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after acquiring an additional 1,347,700 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock worth $26,241,000 after purchasing an additional 160,814 shares during the period. Bank of America Corp DE grew its position in Integra LifeSciences by 71.4% in the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after buying an additional 589,408 shares during the last quarter. Invenomic Capital Management LP grew its position in Integra LifeSciences by 78.3% in the 4th quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock valued at $13,115,000 after buying an additional 463,729 shares during the last quarter. Finally, Glenmede Trust Co. NA increased its stake in shares of Integra LifeSciences by 27.4% during the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares during the period. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Truist Financial upgraded Integra LifeSciences, providing some support for the stock and suggesting improved analyst sentiment. Integra LifeSciences Upgraded at Truist Financial
• Positive Sentiment: BMO Capital Markets lowered its price target to $15 from $18 but retained a “market perform” rating. The revised target remains above the referenced share price, indicating analysts see potential recovery despite reduced expectations. Integra LifeSciences Stock Price Target Lowered at BMO Capital Markets
• Neutral Sentiment: Johnson Fistel announced an investigation into Integra on behalf of investors following the company’s flooding-related outlook cuts and reported 21% stock decline. The announcement does not establish wrongdoing, but it could add legal and reputational uncertainty. Johnson Fistel Investor Alert
• Negative Sentiment: Integra announced preliminary third-quarter 2026 results that include an adverse impact from flooding at its Cincinnati operations and cut its 2026 financial guidance. The disruption raises concerns about near-term revenue, earnings and production performance, making this the primary fundamental headwind for IART. Integra LifeSciences Preliminary Q3 Results and Flooding Impact

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.